Top

International Urogynecology Journal

Published in:

01-07-2013 | Review Article

Botulinum toxin for conditions of the female pelvis

Authors: Dominique El-Khawand, Salim Wehbe, Kristene Whitmore

Published in: International Urogynecology Journal | Issue 7/2013

Abstract

Introduction and hypothesis

Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for those conditions.

Methods

A literature review of the most relevant reports published between 1985 and 2012.

Results

Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain.

Conclusions

Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.

Hanchanale VS, Rao AR, Martin FL, Matanhelia SS (2010) The unusual history and the urological applications of botulinum neurotoxin. Urol Int 85(2):125–130PubMedCrossRef

Leong RK, De Wachter SG, van Kerrebroeck PE (2010) Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 84(3):245–253PubMedCrossRef

Brashear A (2008) Clinical comparisons of botulinum neurotoxin formulations. Neurologist 14(5):289–298PubMedCrossRef

Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29(23):1761–1768PubMedCrossRef

Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742–750PubMedCrossRef

Krhut J, Samal V, Nemec D, Zvara P (2012) Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 50(12):904–907PubMedCrossRef

Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder–to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423–2428PubMedCrossRef

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (12):CD005493

Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422PubMedCrossRef

10.

Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30(4):556–562PubMedCrossRef

11.

Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A (2012) Repeated botulinum toxin type A Injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 61(4):834–839PubMedCrossRef

12.

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D et al (2012) Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 62(3):507–514PubMedCrossRef

13.

Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30(7):1242–1248PubMed

14.

Manecksha RP, Cullen IM, Ahmad S et al (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935PubMedCrossRef

15.

Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178(4 Pt 1):1359–1363PubMedCrossRef

16.

Tirumuru S, Al-Kurdi D, Latthe P (2010) Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J 21(10):1285–1300PubMedCrossRef

17.

Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 104(5):657–661PubMedCrossRef

18.

Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60(4):784–795PubMedCrossRef

19.

Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E (2005) Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76(12):1670–1676PubMedCrossRef

20.

Rao A, Abbott J (2009) Using botulinum toxin for pelvic indications in women. Aust N Z J Obstet Gynaecol 49(4):352–357PubMedCrossRef

21.

Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108(4):915–923PubMedCrossRef

22.

Goldstein AT, Burrows LJ, Kellogg-Spadt S (2011) Intralevator injection of botulinum toxin for the treatment of hypertonic pelvic floor muscle dysfunction and vestibulodynia. J Sex Med 8(5):1287–1290PubMedCrossRef

23.

Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A (2009) Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol 114(5):1008–1016PubMedCrossRef

24.

Haefner HK (2007) Report of the International Society for the Study of Vulvovaginal Disease terminology and classification of vulvodynia. J Low Genit Tract Dis 11(1):48–49PubMedCrossRef

25.

Andrews JC (2011) Vulvodynia interventions—systematic review and evidence grading. Obstet Gynecol Surv 66(5):299–315PubMedCrossRef

26.

Petersen CD, Giraldi A, Lundvall L, Kristensen E (2009) Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 6(9):2523–2537PubMedCrossRef

27.

Yiannakopoulou E (2012) Botulinum toxin and anal fissure: efficacy and safety systematic review. Int J Colorectal Dis 27(1):1–9PubMedCrossRef

28.

Jost WH, Schimrigk K (1993) Use of botulinum toxin in anal fissure. Dis Colon Rectum 36(10):974PubMedCrossRef

29.

Nyam DC, Pemberton JH (1999) Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum 42(10):1306–1310PubMedCrossRef

30.

Valizadeh N, Jalaly NY, Hassanzadeh M et al (2012) Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial. Langenbecks Arch Surg 397(7):1093–1098PubMedCrossRef

31.

Sierra F (2005) Evidence-Based Medicine (EBM) in practice: applying number needed to treat and number needed to harm. Am J Gastroenterol 100(8):1661–1663PubMedCrossRef

32.

Mentes BB, Irkorucu O, Akin M, Leventoglu S, Tatlicioglu E (2003) Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum 46(2):232–237PubMedCrossRef

33.

Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A (2000) Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am J Surg 179(1):46–50PubMedCrossRef

34.

Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G (2007) Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure. Br J Surg 94(2):162–167PubMedCrossRef

35.

Brisinda G, Albanese A, Cadeddu F et al (2004) Botulinum neurotoxin to treat chronic anal fissure: results of a randomized “Botox vs. Dysport” controlled trial. Aliment Pharmacol Ther 19(6):695–701PubMedCrossRef

36.

Preston DM, Lennard-Jones JE (1985) Anismus in chronic constipation. Dig Dis Sci 30(5):413–418PubMedCrossRef

37.

Hompes R, Harmston C, Wijffels N, Jones OM, Cunningham C, Lindsey I (2012) Excellent response rate of anismus to botulinum toxin if rectal prolapse misdiagnosed as anismus (‘pseudoanismus’) is excluded. Colorectal Dis 14(2):224–230PubMedCrossRef

38.

Faried M, El Nakeeb A, Youssef M, Omar W, El Monem HA (2010) Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg 14(8):1235–1243PubMedCrossRef

39.

Rao SS, Tuteja AK, Vellema T, Kempf J, Stessman M (2004) Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 38(8):680–685PubMedCrossRef

40.

Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd (1993) Functional constipation and outlet delay: a population-based study. Gastroenterology 105(3):781–790PubMed

41.

DiPalma JA (2004) Current treatment options for chronic constipation. Rev Gastroenterol Disord 4 [Suppl 2]:S34–S42PubMed

42.

Park UC, Choi SK, Piccirillo MF, Verzaro R, Wexner SD (1996) Patterns of anismus and the relation to biofeedback therapy. Dis Colon Rectum 39(7):768–773PubMedCrossRef

43.

Farid M, El Monem HA, Omar W et al (2009) Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis 24(1):115–120PubMedCrossRef

44.

Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39(10):1107–1111PubMedCrossRef

45.

Shafik A, El-Sibai O (1998) Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg 15(4):347–351PubMedCrossRef

46.

Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A (2000) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43(3):376–380PubMedCrossRef

47.

Ron Y, Avni Y, Lukovetski A et al (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44(12):1821–1826PubMedCrossRef

48.

Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G (2006) Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol 101(11):2570–2575PubMedCrossRef

49.

Hollingshead JR, Maeda Y, Brown TJ, Warusavitarne J, Vaizey CJ (2011) Long-term outcome of the use of botulinum toxin injection for functional anal pain. Colorectal Dis 13(9):e293–e296PubMedCrossRef

50.

Christiansen J, Bruun E, Skjoldbye B, Hagen K (2001) Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum 44(5):661–665PubMedCrossRef

51.

Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 2(8613):714–717PubMedCrossRef

52.

Shepherd JP, Lowder JL, Leng WW, Smith KJ (2011) InterStim sacral neuromodulation and botox botulinum-a toxin intradetrusor injections for refractory urge urinary incontinence: a decision analysis comparing outcomes including efficacy and complications. Female Pelvic Med Reconstr Surg 17(4):199–203PubMedCrossRef

53.

Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM (2009) Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 182(6):2799–2804PubMedCrossRef

54.

Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE (2011) Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 108(4):558–564PubMedCrossRef

55.

Hanno PM, Burks DA, Clemens JQ et al (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185(6):2162–2170PubMedCrossRef

Title: Botulinum toxin for conditions of the female pelvis
Authors: Dominique El-Khawand
Salim Wehbe
Kristene Whitmore
Publication date: 01-07-2013
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 7/2013
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-012-2035-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Botulinum toxin for conditions of the female pelvis

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2013

The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR)

Impact of staged InterStim® implantation on the postoperative activities of daily living and pain

Work-related musculoskeletal disorders among vaginal surgeons

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

Lack of effect of concomitant stage II cystocele repair on lower urinary tract symptoms and surgical outcome after tension-free vaginal tape procedure: randomized controlled trial

Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up